URGN UroGen Pharma Ltd.
Healthcare$29.51+0.00%OpenMarket Cap: $1.44B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-11.67
P/S
10.02
EV/EBITDA
-12.83
DCF Value
$-30.43
FCF Yield
-11.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.9%
Operating Margin
-77.0%
Net Margin
-94.8%
ROE
121.5%
ROA
-52.5%
ROIC
-50.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $51.0M | 91.9% | $-20.3M | $-23.6M | $— | — |
| Q4 null | $37.8M | 91.3% | $-19.1M | $-26.4M | $— | — |
| FY null | $109.8M | 88.7% | $-124.9M | $-153.5M | $— | — |
| Q3 null | $27.5M | 88.1% | $-27.4M | $-33.3M | $— | — |
| Q2 null | $24.2M | 85.3% | $-41.4M | $-49.9M | $— | — |
| Q1 null | $20.3M | 88.5% | $-36.9M | $-43.8M | $— | — |
| Q4 null | $24.6M | 89.9% | $-27.7M | $-37.5M | $— | — |
| FY null | $90.4M | 90.2% | $-96.8M | $-126.9M | $— | — |
| Q3 null | $25.2M | 90.3% | $-17.5M | $-23.7M | $— | — |
| Q2 null | $21.8M | 89.8% | $-25.8M | $-33.4M | $— | — |
| Q1 null | $18.8M | 90.8% | $-25.7M | $-32.3M | $— | — |
| Q4 2023 | $23.5M | 90.3% | $-14.6M | $-26.0M | $-0.72 | — |